Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

Purpose: The E75 peptide is an immunogenic peptide from the HER-2/ neu protein that is substantially expressed in prostate cancer. We are conducting a clinical trial of an E75/granulocyte macrophage colony-stimulating factor vaccine to prevent post-prostatectomy prostate-specific antigen (PSA) recur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2005-10, Vol.11 (20), p.7470-7479
Hauptverfasser:	HUEMAN, Matthew T, DEHQANZADA, Zia A, PONNIAH, Sathibalan, PEOPLES, George E, NOVAK, Thomas E, GURNEY, Jennifer M, WOLL, Michael M, RYAN, Gayle B, STORRER, Catherine E, FISHER, Christine, MCLEOD, David G, IOANNIDES, Constantine G
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic agents Biological and medical sciences Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Cell Line, Tumor clinical trial Cytotoxicity Tests, Immunologic Cytotoxicity, Immunologic Gynecology. Andrology. Obstetrics HER-2 HLA-A2 Antigen - immunology Humans Immunotherapy Interferon-gamma - biosynthesis Leukocytes, Mononuclear - immunology Leukocytes, Mononuclear - metabolism Male Male genital diseases Medical sciences Middle Aged Neoplasm Recurrence, Local Nephrology. Urinary tract diseases neu Peptide Fragments - immunology Pharmacology. Drug treatments prevention Prognosis prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - immunology Prostatic Neoplasms - pathology Prostatic Neoplasms - prevention & control Receptor, ErbB-2 - chemistry Receptor, ErbB-2 - immunology Risk Factors Time Factors Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland vaccine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!